4/17
07:42 am
acet
Adicet Bio Appoints Michael Grissinger to the Board of Directors [Yahoo! Finance]
Medium
Report
Adicet Bio Appoints Michael Grissinger to the Board of Directors [Yahoo! Finance]
4/17
07:00 am
acet
Adicet Bio Appoints Michael Grissinger to the Board of Directors
Medium
Report
Adicet Bio Appoints Michael Grissinger to the Board of Directors
3/31
05:12 pm
acet
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/31
07:11 am
acet
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference [Yahoo! Finance]
Medium
Report
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference [Yahoo! Finance]
3/31
07:00 am
acet
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
Medium
Report
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
3/23
08:50 am
acet
Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
High
Report
Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
3/21
10:07 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $7.00 price target on the stock.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $7.00 price target on the stock.
3/7
08:13 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
3/6
04:42 pm
acet
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]
Medium
Report
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]
3/6
04:01 pm
acet
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
Medium
Report
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
3/3
07:07 am
acet
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting [Yahoo! Finance]
Medium
Report
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting [Yahoo! Finance]
3/3
07:00 am
acet
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
Medium
Report
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
2/27
09:22 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
2/27
07:45 am
acet
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) [Yahoo! Finance]
Medium
Report
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) [Yahoo! Finance]
2/27
07:00 am
acet
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
High
Report
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
2/6
10:30 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "market perform" rating re-affirmed by analysts at JMP Securities.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "market perform" rating re-affirmed by analysts at JMP Securities.
2/5
10:26 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
2/5
08:47 am
acet
Adicet Bio receives FDA fast track designation for its lupus erythematosus treatment [Seeking Alpha]
Medium
Report
Adicet Bio receives FDA fast track designation for its lupus erythematosus treatment [Seeking Alpha]
2/5
07:10 am
acet
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
Medium
Report
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
1/31
06:06 pm
acet
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/29
07:26 am
acet
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference [Yahoo! Finance]
Low
Report
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference [Yahoo! Finance]
1/29
07:00 am
acet
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
Low
Report
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference